PlainPharmaWatch

CMS Open Payments · Tool

Mirati Therapeutics, Inc. vs Braintree Laboratories, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Braintree Laboratories, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,132, versus 171 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Mirati Therapeutics, Inc.
HHI 171 · top recipient 0.1%
Ranked #1,588 of 1,838 companies by HHI
Braintree Laboratories, Inc.
HHI 2,132 · top recipient 0.3%
Ranked #728 of 1,838 companies by HHI

Payment Overview

Total Payments
$33.7M
% of Industry
0.2%
Transactions
5,618
Avg per Transaction
$6.0K
Recipients
4,888
Avg per Recipient
$6.9K
Payment Types
7
Top Payment Type
Food and Beverage
Total Payments
$33.9M
% of Industry
0.2%
Transactions
8,836
Avg per Transaction
$3.8K
Recipients
5,369
Avg per Recipient
$6.3K
Payment Types
6
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Mirati Therapeutics, Inc. vs Braintree Laboratories, Inc. - total reported payments in CMS Open Payments PY2024

Braintree Laboratories, Inc.$33.9MMirati Therapeutics, Inc.$33.7M

Payment Types Breakdown

Mirati Therapeutics, Inc.

Food and Beverage $110.0K

0.3%

Honoraria $84.9K

0.3%

Space Rental or Facility Fees $48.7K

0.1%

Consulting Fee $42.6K

0.1%

Travel and Lodging $30.5K

0.1%

Grant $5.0K

0.0%

Braintree Laboratories, Inc.

Royalty or License $382.1K

1.1%

Consulting Fee $144.9K

0.4%

Food and Beverage $106.6K

0.3%

Gift $12.9K

0.0%

Grant $5.5K

0.0%

Education $80.85

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Mirati Therapeutics, Inc.

  1. 1

    HATIM HUSAIN

    $23,014.63 · 13 txns

  2. 2

    KATHRYN C. ARBOUR

    $15,668.80 · 5 txns

  3. 3

    MOHAMED MOHAMED

    $12,474.52 · 11 txns

  4. 4

    MARTIN DIETRICH

    $11,195.63 · 13 txns

  5. 5

    EUGENE MUCHNIK

    $9,723.00 · 9 txns

Braintree Laboratories, Inc.

  1. 1

    JOHN FORDTRAN

    $224,157.00 · 8 txns

  2. 2

    GLENN DAVIS

    $157,911.49 · 4 txns

  3. 3

    JACK DIPALMA

    $124,029.21 · 12 txns

  4. 4

    FRANCIS FARRAYE

    $5,000.00 · 1 txns

  5. 5

    DANIEL JOHN PAMBIANCO

    $4,039.33 · 2 txns

Summary Comparison

Metric Mirati Therapeutics, Inc. Braintree Laboratories, Inc.
Total Payments $33.7M $33.9M
% of Industry Total 0.2% 0.2%
Transaction Count 5,618 8,836
Avg per Transaction $6.0K $3.8K
Recipient Count 4,888 5,369
Avg per Recipient $6.9K $6.3K
Payment Type Count 7 6
Top Payment Type Food and Beverage Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.